Investors got jittery on Friday, and for good reason: like all allogeneic cell therapy players Adicet is seeing patients relapse.
Astrazeneca and Ionis’s discontinuation could herald a nervous time for others in this space.
Data in the desmoid tumour niche look strong, but Ayala might provide a cheaper way for investors to play in gamma secretase inhibition.
Asset prices fall sufficiently to persuade Roche to sign up to Poseida’s allogeneic cell therapies.
The recently listed company’s investors get déjà vu with the first human data from a trial of the allogeneic cell therapy CB-010.